Get started
Author

Maria Pouyiourou

Observed name: M. Pouyiourou
ORCID: 0000-0001-9296-3784
Observed ORCID: 0000-0001-9296-3784
OpenAlex ID: A5026005168
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
2023 · Maria Pouyiourou, Bianca N. Kraft, et al. · Nature Communications · 45
PDF
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
2021 · Maria Pouyiourou, Timothy Wohlfromm, et al. · European Journal of Cancer · 19
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
2020 · M. Pouyiourou, A. Meyer, et al. · Annals of Hematology · 17
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
2025 · Maria Pouyiourou, Tilmann Bochtler, et al. · Nature Reviews Clinical Oncology · 16
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
2022 · Tilmann Bochtler, Timothy Wohlfromm, et al. · Genes Chromosomes and Cancer · 14
PDF
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
2024 · Maria Pouyiourou, Tilmann Bochtler, et al. · Clinical Chemistry · 9
PDF
Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich
2023 · Maria Pouyiourou, Sebastian Regnery, et al. · Die Radiologie · 7
CUP-Syndrom – die neue ESMO-Leitlinie
2023 · Tilmann Bochtler, Maria Pouyiourou, et al. · Die Radiologie · 5
Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
2020 · G. R. Boeckel, M. Pouyiourou, et al. · best practice onkologie · 4
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
2022 · M. Pouyiourou, B. Kraft, et al. · Annals of Oncology · 3
Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown Primary
2026 · Jana Löptien, Maximilian Haas, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients
2026 · Anna-Maria Spektor, Sergio Armando Zapata Bonilla, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1
PDF
189eP Comprehensive genomic profiling of circulating cell-free DNA in cancer of unknown primary
2025 · J. Löptien, M. Haas, et al. · Annals of Oncology · 1
174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
2023 · M. Pouyiourou, S. Riethdorf, et al. · Annals of Oncology · 1
PDF
Das CUP-Syndrom - Stand 2020
2020 · Maria Pouyiourou, Laura Claßen, et al. · InFo Hämatologie + Onkologie · 1
3032eP Tissue-specific effects of BAP1 loss on metastatic properties of tumor cell lines
2025 · E. Kharitonova, S. Scholz, et al. · Annals of Oncology
PDF
56/w mit Rückenschmerzen und Nachtschweiß: Vorbereitung auf die Facharztprüfung: Fall 51
2025 · Maria Pouyiourou, Tilmann Bochtler, et al. · Die Onkologie
185P Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
2024 · M. Pouyiourou, G. Zaun, et al. · Annals of Oncology
PDF
Cancer of unknown primary derived from regressed breast cancer
2024 · Maria Pouyiourou, Theresa Mokry, et al. · Journal of Cancer Research and Clinical Oncology
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023
2024 · Maria Pouyiourou, Lea Elisabeth Reitnauer, et al. · Oncology Research and Treatment
PDF
CUP-Syndrom – die neue ESMO-Leitlinie
2023 · Tilmann Bochtler, Maria Pouyiourou, et al. · best practice onkologie
Works count: 21
Citation count: 144
H-index: 7
I10-index: 5
Year
Topic
Type